Concor AM is primarily used for the continuous management of Essential Hypertension. This fixed-dose combination is generally applied in addressing the chronic condition of high blood pressure, contributing to easing the overall symptom load related to systemic and organ-specific functional stress. The medication helps with managing blood pressure levels by addressing both the systemic pressure and the force of the heart, which may assist with managing the risks associated with high blood pressure.

The primary indications for this combination are relevant for easing challenging symptoms in the long-term management of Essential Hypertension, providing supportive relief against cardiovascular stress, and serving as substitution therapy for treatment consistency.

“The reduction in 'pill burden' supports patient adherence to the prescribed long-term regimen.”

This combination is considered relevant in clinical scenarios where a patient requires two distinct antihypertensive agents simultaneously. This regimen assists with maintaining functional stability by helping patients cope more steadily with symptom fluctuations.

---

Quick Fact: Relief for Sustained Blood Pressure Elevation

The combination supports patients by managing the chronic physiological strain created by elevated arterial pressure, which is a key factor in mitigating long-term organ stress.

Regulatory References

1. Philippine Food and Drug Administration (FDA) prescribing information

Concor AM (Amlodipine/Bisoprolol) is officially approved for adult patients (ge 18 years) with essential hypertension who are already adequately controlled on the individual components as separate tablets (substitution therapy). The medicine is not recommended for use in children and adolescents below the age of 18, as its safety and efficacy in the pediatric population have not been established. The regulatory labeling lists several absolute contraindications that prohibit its use.

Population Status	Condition or Limitation (Official Regulatory Classification)
Contraindicated	Acute heart failure, cardiogenic shock, second/third degree AV block (without a pacemaker), symptomatic bradycardia, severe hypotension, severe asthma, untreated pheochromocytoma, or metabolic acidosis.
Use Not Recommended	Pregnancy or lactation (breastfeeding).
Restricted Use	Severe renal impairment (CrCl < 20 ml/min) or severe hepatic impairment, where the bisoprolol component must not exceed 10 mg daily.

Use also requires special caution in patients with conditions like first degree AV block, Prinzmetal's angina, and diabetes mellitus with large fluctuations in blood glucose values. These regulatory criteria strictly define the eligible patient population.

Concor AM, a fixed-dose combination of Amlodipine and Bisoprolol, has officially documented interaction patterns primarily involving metabolic pathways and additive physiological effects.

Pharmacokinetic Interactions (Exposure Modification)

Interactions affecting the Amlodipine component are often mediated by the Cytochrome P450 3A4 (CYP3A4) enzyme system. Co-administration with strong or moderate CYP3A4 Inhibitors, such as Diltiazem, Itraconazole, and certain macrolides, may lead to a significant increase in Amlodipine plasma concentration. Conversely, co-administration with CYP3A4 Inducers, including Rifampicin and the herbal product St. John's Wort, may result in a lower Amlodipine plasma concentration.

Pharmacodynamic Effects and Regulatory Restrictions

Official regulatory documents state that co-administration with other Beta-Blocking Agents is formally contraindicated due to the risk of excessive beta-adrenergic blockade from the Bisoprolol component. The combination with catecholamine-depleting drugs (e.g., Reserpine) may produce an excessive reduction of sympathetic activity.

A specific timing rule exists for combination with Clonidine: the Bisoprolol component must be discontinued for several days before the withdrawal of Clonidine. Administration with grapefruit or grapefruit juice is not recommended as Amlodipine's bioavailability may be increased. For elderly patients and those with hepatic impairment, reduced Amlodipine clearance is documented, which is a population-specific consideration for exposure.

How Concor AM Works: Mechanism of Action

Dampening Sympathetic Drive and Cardiac Workload

This mechanism focuses on Bisoprolol's highly selective antagonism of beta1 adrenergic receptors in the heart and kidneys. By blocking the influence of stress hormones (catecholamines), this action initiates a sequential decrease in the heart's rate and force of contraction (negative chronotropy and inotropy). This dampening mechanism lowers the myocardial oxygen demand and suppresses the beta1-mediated release of renin, thereby modulating key components of the cardiovascular regulatory system.

---

Modulating Vascular Tone via Calcium Channel Blockade

The peripheral action of Amlodipine is centered on the non-competitive blockade of L-type Voltage-Gated Calcium Channels (VGCCs) found in the smooth muscle cells of the arteries. This key interaction prevents the necessary influx of calcium ions, leading to the relaxation of arterial walls (vasodilation). The physiological consequence is a reduction in the Systemic Vascular Resistance (SVR), decreasing the resistance against which the heart pumps.

---

Dual-Pathway Synergy and Reflex Counteraction

The combination engages two distinct physiological pathways—cardiac output and peripheral resistance—to address two distinct hemodynamic components. Bisoprolol’s action provides a mechanistic counter-regulatory action by modulating the potential reflex tachycardia (compensatory heart rate increase) that can sometimes be triggered by Amlodipine’s vasodilation, which stabilizes the chronotropic response.

How to Use Concor AM (Amlodipine/Bisoprolol)

Concor AM is a fixed-dose combination (FDC) therapy. This medication is administered orally in the form of a tablet and is typically taken once daily in the morning. The administration may occur with or without food.

Dosing and Administration

The standard adult dosing regimen involves taking one tablet of the prescribed strength daily, corresponding to the specific combination of Bisoprolol and Amlodipine (e.g., 5 mg/5 mg or 10 mg/10 mg). The highest available strength, 10 mg Bisoprolol / 10 mg Amlodipine, is the maximum recommended daily dose for the FDC. This FDC is commonly used as a substitution therapy for patients already stabilized on the individual components.

The tablet must be swallowed whole and should not be chewed. If the tablet is scored, the line is intended only to aid in swallowing, not for dividing the tablet into smaller doses.

Population Group	Official Dosing Instruction
Pediatric (under 18)	Use is not recommended; safety and efficacy are not established.
Severe Hepatic/Renal Impairment	The Bisoprolol component must not exceed 10 mg daily.

Treatment with this medication is intended for long-term management. To avoid a temporary worsening of the clinical condition, particularly in patients with heart issues, the therapy must not be stopped abruptly; gradual dose reduction is required.

Overview of Studies for Concor AM (Amlodipine/Bisoprolol)

---

Evidence for Use in Managing Essential Hypertension

Research has focused extensively on the Amlodipine/Bisoprolol fixed-dose combination (FDC) for the management of high blood pressure, the primary condition studied. Studies specifically examined the use of this combination in adult patients who had previously not reached their blood pressure targets while taking Amlodipine or Bisoprolol alone. Research consisted primarily of short-term to intermediate-term Randomized Controlled Trials (RCTs). These studies explored changes in core outcomes like Systolic and Diastolic Blood Pressure (SBP/DBP) measurements and the percentage of participants who achieved predefined blood pressure goals.

Trials compared the FDC groups to monotherapy groups, and the research monitored different measurement patterns for SBP and DBP at the study endpoint. Research describes the evolution of symptom-related measurements, showing that a greater number of participants in the FDC groups met the predefined blood pressure control targets. These primary efficacy studies were typically short-term, meaning their findings provide limited insight into long-term health outcomes.

---

Studies on Patient Adherence and Treatment Consistency

Observational research examined patient adherence, which is an outcome related to systemic treatment consistency. These large, non-interventional studies were used in observational settings evaluating daily-life functioning and how patients maintained their prescribed regimen over time. Studies compared patients who took the Amlodipine and Bisoprolol components as two separate pills versus those who took the single FDC tablet.

This research consistently reports that when participants switched from separate pills to the FDC tablet, the studies monitored different patterns in the rates of treatment adherence. These findings describe patterns related to patient adherence and help contextualize how participants reported their experience. Research does not determine whether an individual will respond similarly, but findings describe group patterns related to treatment persistence.

---

Areas of Research Uncertainty and Study Gaps

Despite the available evidence from RCTs and observational studies, certain aspects of the FDC's profile have limited information. The core research largely focused on blood pressure measurement, and there is limited information for long-term outcomes specifically from prospective trials comparing the FDC against the equivalent free-dose regimen. Data for certain groups remain insufficient, meaning the results apply most directly to the populations studied in the original research. Follow-up durations were limited in the primary efficacy studies.

Key Studies & References

1. Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study
2. Treatment of hypertension with a fixed-dose combination of bisoprolol and amlodipine in daily practice: Results of a multinational non-investigational study
3. Public Assessment Report for Bisoprolol Fumarate + Amlodipine (Concore AM) (Regulatory Documentation/Indication)

Common questions about Concor AM (Amlodipine) (FAQ)

Q: Is Concor AM the brand name for the combination of bisoprolol and amlodipine?

Concor AM is the proprietary (brand) name given to the tablet that combines the two active pharmaceutical ingredients, amlodipine and bisoprolol, into a single fixed dose. This designation is consistent with information provided in the official product labeling.

Q: How long after starting Concor AM should my blood pressure drop?

Official information indicates that the blood pressure-lowering effect from the amlodipine component typically begins relatively quickly, with peak plasma levels reached between 6 and 12 hours after dosing. However, the maximal antihypertensive effect from the bisoprolol component may require a longer period, generally reaching its peak after approximately two weeks of consistent treatment.

Q: Is it possible for the medicine to take a few weeks to reach its full effect?

Official regulatory documents describe that the full blood pressure effect is not immediate. The maximal effect of the bisoprolol component, one of the two active drugs in the combination, is generally reached after about two weeks of continuous therapy.

Q: Does a single daily dose of Concor AM continue to work for a full 24 hours?

Pharmacological data shows that both the amlodipine and bisoprolol components have long half-lives, meaning they remain in the body for an extended period. These long half-lives support a 24-hour duration of action, which is a key property of the medication.

Q: Can Concor AM affect sleep patterns or cause insomnia?

According to official product information, insomnia (difficulty sleeping) is listed as an uncommon side effect associated with the amlodipine component of the drug. This finding is included in the official safety information.

Q: Can Concor AM cause changes to sexual function or libido?

Official labeling for the individual components lists changes to sexual function. Impotence (erectile dysfunction) is listed as an uncommon side effect for amlodipine and a rare side effect for bisoprolol. Gynecomastia (breast enlargement) is also listed as an uncommon side effect for amlodipine.

Q: What is the likelihood of experiencing muscle cramps or joint pain with this medication?

Official safety data indicates that muscle cramps are classified as a common side effect associated with the amlodipine component. Additionally, arthralgia (joint pain) and myalgia (muscle pain) are listed as uncommon side effects for the same component.

Q: Are there any reported instances of weight change (gain or loss) linked to Concor AM?

The official product information lists both weight increased and weight decreased as uncommon side effects related to the amlodipine component of the medicine. These findings are noted in the safety documentation.

Q: What is the official stance on consuming alcohol while taking this medicine?

Regulatory information indicates that alcohol may have additive effects with both components in lowering blood pressure. This effect may increase the potential for side effects such as dizziness or lightheadedness.

Q: Does Concor AM interact with common cholesterol-lowering medicines (statins)?

The amlodipine component is known to interact with certain statins, specifically simvastatin and lovastatin. This interaction can increase the statin concentration in the body, which is a documented pharmacokinetic consideration.

Q: Can Concor AM affect my ability to drive or operate machinery?

Official safety data indicates that this medication can have a mild to moderate influence on the ability to drive or use machines. Common side effects such as dizziness, headache, or fatigue can occur, particularly when treatment is first started or when doses are changed. Patients are advised that their ability to drive or use machinery may be impaired.

Storage and Disposal Requirements for Concor AM (Bisoprolol/Amlodipine)

Concor AM tablets must be stored according to official regulatory labeling to ensure product stability and safety.

Storage Conditions

The medicine requires temperature control and protection from environmental factors:

• Temperature: Do not store the tablets above 30 C (86 F). The medicine should not be frozen.
• Protection: The tablets must be protected from both direct light and moisture.
• Packaging: Store the product in its original container or packet and keep it tightly closed.
• Child Safety: It is mandatory to keep the medicine out of the sight and out of the reach of children.

Disposal Instructions

Unused, expired, or no longer needed tablets must be handled responsibly. Regulatory documents specify that the medicine should not be disposed of via wastewater or typical household waste. Disposal of the medicinal product and waste materials must be performed according to local regulations, often by returning the items to a pharmacist or local collection point.